anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The temporal component of episodic memory has been recognized as a sensitive behavioral marker in early stage of Alzheimer's disease (AD) patients. However, parallel studies in AD animals are currently lacking, and the underlying neural circuit mechanisms remain poorly understood. Using a novel AppNL-G-F knock-in (APP-KI) rat model, the developmental changes of temporal order memory (TOM) and the relationship with medial prefrontal cortex and perirhinal cortex (mPFC-PRH) circuit were determined through in vivo electrophysiology and microimaging technique. We observed a deficit in TOM performance during the object temporal order memory task (OTOMT) in APP-KI rats at 6 month old, which was not evident at 3 or 4 months of age. Alongside behavioral changes, we identified a gradually extensive and aggravated regional activation and functional alterations in the mPFC and PRH during the performance of OTOMT, which occurred prior to the onset of TOM deficits. Moreover, coherence analysis showed that the functional connectivity between the mPFC and PRH could predict the extent of future behavioral performance. Further analysis revealed that the aberrant mPFC-PRH interaction mainly attributed to the progressive deterioration of synaptic transmission, information flow and network coordination from mPFC to PRH, suggesting the mPFC dysfunction maybe the key area of origin underlying the early changes of TOM. These findings identify a pivotal role of the mPFC-PRH circuit in mediating the TOM deficits in the early stage of AD, which holds promising clinical translational value and offers potential early biological markers for predicting AD memory progression.
BACKGROUND: Acute high-risk abdominal (AHA) surgery is associated with a high short-term mortality rate. This might be partly attributed to myocardial injury after non-cardiac surgery (MINS) defined by elevated postoperative troponin levels. The myocardial injury is often asymptomatic; thus, troponin screening seems to be the best diagnostic method. We aimed to assess whether implementing troponin screening with subsequent individualised interventions as standard care is associated with reduced mortality after AHA surgery. We also explored the treatment implications in the screening period.
METHODS: A retrospective cohort of 558 patients undergoing surgery from February 2018 to March 2021 was included. The patients undergoing surgery before March 2019 served as the historical control group, while the screening group consisted of patients undergoing surgery from March 1, 2019. Troponin I was to be measured 6-12 h postoperatively and in the morning of the succeeding 4 days. Patients with myocardial injury were assessed, and treatment was individualised after multiple disciplinary consultations. The primary outcome was the unadjusted 30-day mortality rates. Inverse probability treatment weighting was used to adjust for selection bias.
RESULTS: We included 558 patients: 382 in the screening group and 176 in the historical control group. In the screening group, 15 patients (3.9%) died before the first blood sampling, and in 31 patients (8.1%), troponin screening was omitted, leaving only 336 patients screened. Myocardial injury was diagnosed in 81 patients (24.1%) of the 336 patients. Of these, 59 (72.8%) had a cardiac consultation. No interventions or alterations in relation to myocardial injury were done in 67 patients (82.7%). The 30-day mortality was 13.8% (95% CI 8.7%-18.9%) in the control group and 11.1% (95% CI 8.0%-14.3%) in the screening group. The absolute risk difference was -2.7% (95% CI -8.7%-3.3%; p = .38), which was unchanged after adjustment. The difference remained unchanged after 90 days and 1 year.
CONCLUSION: The implementation of postoperative troponin screening was not associated with reduced mortality after AHA surgery. Research on the prevention and treatment of MINS is warranted before the implementation of standard troponin screening.
A method of treating pain in provided. The method comprises administering to the intrinsic spinal muscles of a mammal an amount of a toxin sufficient to paralyze the muscles. This prevents the muscles from shortening and can allow healing to occur. The paralyzing agent may use in combination with a growth factor to treat spinal compression. A kit for the treatment of pain by injection of the intrinsic spinal muscles is also provided. The kit comprises a paralyzing agent, an injection syringe with needle, and an acupuncture needle with injector system.
The present invention provides a water-in-oil emulsion composition that is very excellent in emulsion stability and excellent in non-stickiness. The water-in-oil emulsified composition comprises: (a) 0.5-3 mass% of polyoxyalkylene/alkyl co-modified silicone, (b) 0.01 mass% or more of core-corona type particle, (c) an oil phase component, and (d) a water phase component; wherein the (b) core-corona type particle is a core-corona particle obtained by radical polymerization of a polyethylene oxide macromonomer represented by the following formula (1) with a hydrophobic monomer selected from an acrylic acid/methacrylic acid derivative monomer represented by the following formula (2) and an acrylamide/ methacrylamide derivative monomer represented by the following formula (3), in the presence or absence of a crosslinkable monomer represented by the following formula (4) under the following conditions (A) to (E). (A) the molar ratio represented by the charged molar amount of the polyethylene oxide macromonomer/ the charged molar amount of the hydrophobic monomer is 1:10 to 1:250. (B) the charge amount of the crosslinkable monomer is 0.1 to 1.5 mass% with respect to the charge amount of the hydrophobic monomer. (C) the acrylic acid/methacrylic acid derivative monomer represented by the following formula (2) is a monomer composition in which one or more methacrylic acid derivatives containing an alkyl group having 1 to 8 carbon atoms are mixed, and the acrylamide/methacrylamide derivative monomer represented by the following formula (3) is an acrylamide derivative or a methacrylamide derivative having a substituent containing an alkyl group having 1 to 18 carbon atoms. (D) the polymerization solvent is a water-alcohol mixed solvent, and the alcohol is one or more selected from ethanol, dipropylene glycol, 1,3-butylene glycol, and isoprene glycol. (E) the solvent composition of the water-alcohol mixed solvent is water: alcohol = 90 to 10:10 to 90 in view of mass ratio at 20 DEG C. R1 represents an alkyl group having 1 to 3 carbon atoms, and n is a number of 8 to 200. X represents H or CH3. R2 represents an alkyl group having 1 to 3 carbon atoms, and R3 represents an alkyl group having 1 to 12 carbon atoms. R4 represents H or an alkyl group having 1 to 3 carbon atoms, and R5 and R6 represent H or a substituent containing an alkyl group having 1 to 18 carbon atoms. R7 and R8 each independently represents an alkyl group having 1 to 3 carbon atoms, and m is a number from 0 to 2.
Numerous studies on post-COVID syndrome (PCS) describe persisting symptoms of cognitive impairment. Previous studies, however, often investigated small samples or did not assess covariates possibly linked to cognitive performance. We aimed to describe 1) global and domain-specific cognitive performance in adults with PCS, controls with previous SARS-CoV-2 infection and healthy controls, 2) associations of sociodemographics, depressive symptoms, anxiety, fatigue, somatic symptoms and stress with cognitive performance and subjective cognitive decline (SCD), using data of the LIFE-Long-COVID-Study from Leipzig, Germany. Group differences in cognitive performance and associations with sociodemographic and neuropsychiatric covariates were assessed using multivariable regression analyses. Our study included n = 561 adults (Mage: 48.8, SD: 12.7; % female: 70.6). Adults with PCS (n = 410) performed worse in tests on episodic memory (b = -1.07, 95 % CI: -1.66, -0.48) and visuospatial abilities (b = -3.92, 95 % CI: -6.01, -1.83) compared to healthy controls (n = 64). No impairments were detected for executive function, verbal fluency, and global cognitive performance. Odds of SCD were not higher in PCS. A previous SARS-CoV-2 infection without PCS (n = 87) was not linked to cognitive impairment. Higher age and higher levels of stress and fatigue were linked to worse performance in several cognitive domains. Routine administration of tests for episodic memory and visuospatial abilities might aid in the identification of individuals at risk for cognitive impairment when reporting symptoms of PCS. Low numbers of participants with severe COVID-19 infections possibly limit generalizability of our findings.
PURPOSE: To compare the hearing results and clinical safety of patients undergoing stapes surgery with conventional technique and diode laser.
METHODS: Retrospective observational study, which included patients treated with primary stapes surgery performed between January 2009 and January 2020. Three audiometric measurements (PTA, GAP and SDS) were evaluated as main results, evaluated by analysis of covariance (controlling the preoperative value). Intraoperative and postoperative complications were also analyzed. Outcomes were measured 6 months (± 1 month) after surgery.
RESULTS: 153 cases were included, 97 operated with conventional technique and 56 with laser technique. Postoperative GAP ≤ 10 dB was obtained in 85.6% of the total sample, 82.5% in the conventional technique and 91.1% in the laser technique. Analysis of covariance showed no significant differences in the three surgery outcomes between the two groups (PTA, p = 0.277; GAP, p = 0.509 and SDS, p = 0.530). Regarding surgical complications, sensorineural damage was higher in the conventional technique group (p = 0.05). On the other hand, there were four cases of facial paresis, all in the laser group, three of them with the 980 nm laser.
CONCLUSIONS: Stapedotomy offered a high percentage of hearing success in the two groups studied. There were no significant differences in audiometric result, but there was a differential presentation of complications, being more frequent sensorineural hearing loss in the conventional technique group and facial paresis in the laser group.
PURPOSE: A ferric oxide complex nanoparticle is provided to be selectively combined to activated macrophages in a stable form in the aqueous environment by being coated with a block copolymer containing dextran sulfate and polyglycerol monomethacrylate (PGMA). CONSTITUTION: A ferric oxide complex nanoparticle contains the ferric oxide complex nanoparticle and a block copolymer coating the surface of the nanoparticle. The end of dextran sulfate of the block copolymer consists polyglycerol monomethacrylate. The block copolymer is denoted by chemical formula 1. In the chemical formula 1, n is a fixed number of 10-1,000, and m is a fixed number of 2-1,000. A producing method of the ferric oxide complex nanoparticle comprises the following steps: producing polyglycerol monomethacrylate by radical-polymerizing using glycerol monomethacrylate as a chain transfer agent, and cysteamine; reacting the polyglycerol monomethacrylate with dextran sulfate to obtain the block copolymer; and coating the ferric oxide complex nanoparticle with the block copolymer.
Metal is placed onto the skin at a temperature of -2 degrees Celsius for 30 seconds. A thermal imaging camera will be used to identify how long it takes for the skin to return to its initial temperature.
Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease that affects millions of people worldwide, and current treatment methods have certain limitations. This study aimed to explore the therapeutic potential and mechanism of action of lemairamin (Wgx-50) in inflammatory bowel disease (IBD). We used dextran sulfate sodium (DSS)-treated zebrafish as an inflammatory bowel disease model, and observed the effect of Wgx-50 on DSS-induced colitis inflammation. The results of the study showed that Wgx-50 could reduce the expression of pro-inflammatory cytokines induced by DSS and inhibit the recruitment of neutrophils to the site of intestinal injury. Further experiments revealed that Wgx-50 exerted its anti-inflammatory effect by regulating the activation of the Akt pathway. These research findings indicate that Wgx-50 possesses anti-inflammatory activity.
Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.
Clinical identification of individuals with mechanical low back pain who would benefit from a program of stabilization exercises has been a struggle for the physical therapy profession. While changes in trunk muscle recruitment and motor control have been linked to patients with chronic low back pain and hypothesized to be adaptations for spinal instability, this has not been systematically established. However, a connection between spinal instability, poor trunk motor control, and low back pain is plausible. The real problem lies with the clinical identification of the subgroup of patients in either the acute or chronic phases of low back dysfunction who would most benefit from this approach to intervention.

In creating their preliminary clinical prediction rule, Hicks et al (2005), looked at many variables including patient demographics and characteristics, hip and trunk motion, special tests for instability, and functional measures of muscle performance. However, measures of the performance of core stabilizing muscles and assessment of trunk dynamic control/ coordination were not included as potential variables. The aim of this study is to determine if assessment of additional measures of trunk neuromuscular control will improve the ability to identify patients with low back pain who successfully respond to trunk stabilization exercises.
Loss-of-function variants in the triggering receptor expressed on myeloid cells 2 (TREM2) are responsible for a spectrum of neurodegenerative disorders. In the homozygous state, they cause severe pathologies with early onset dementia, such as Nasu-Hakola disease and behavioural variants of frontotemporal dementia (FTD), whereas heterozygous variants increase the risk of late-onset Alzheimer's disease (AD) and FTD. For over half of TREM2 variants found in families with recessive early onset dementia, the defect occurs at the transcript level via premature termination codons or aberrant splicing. The remaining variants are missense alterations thought to affect the protein; however, the underlying pathogenic mechanism is less clear. In this work, we tested whether these disease-associated TREM2 variants contribute to the pathology via altered splicing. Variants scored by SpliceAI algorithm were tested by a full-size TREM2 splicing reporter assay in different cell lines. The effect of variants was quantified by qRT-/RT-PCR and western blots. Nanostring nCounter was used to measure TREM2 RNA in the brains of NHD patients who carried spliceogenic variants. Exon skipping events were analysed from brain RNA-Seq datasets available through the Accelerating Medicines Partnership for Alzheimer's Disease Consortium. We found that for some Nasu-Hakola disease and early onset FTD-causing variants, splicing defects were the primary cause (D134G) or likely contributor to pathogenicity (V126G and K186N). Similar but milder effects on splicing of exons 2 and 3 were demonstrated for A130V, L133L and R136W enriched in patients with dementia. Moreover, the two most frequent missense variants associated with AD/FTD risk in European and African ancestries (R62H, 1% in Caucasians and T96K, 12% in Africans) had splicing defects via excessive skipping of exon 2 and overproduction of a potentially antagonistic TREM2 protein isoform. The effect of R62H on exon 2 skipping was confirmed in three independent brain RNA-Seq datasets. Our findings revealed an unanticipated complexity of pathogenic variation in TREM2, in which effects on post-transcriptional gene regulation and protein function often coexist. This necessitates the inclusion of computational and experimental analyses of splicing and mRNA processing for a better understanding of genetic variation in disease.
<P>PROBLEM TO BE SOLVED: To provide a stable solid preparation of egualen sodium that is suppressed in formation of a decomposate of egualen sodium during storage.  <P>SOLUTION: The solid preparation of egualen sodium has incorporated therewith at least one additive selected from among povidone, a derivative thereof and an additive exhibiting basicity. Preferably, the povidone derivative is crospovidone. Preferably, the additive exhibiting basicity is a basic inorganic compound selected from among magnesium carbonate, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium carbonate, sodium hydrogen carbonate and sodium hydroxide, or a basic organic compound selected from among arginine, lysine, histidine and ornithine. The solid preparation of egualen sodium has incorporated therewith an additive exhibiting basicity in a sufficient amount to make the pH of an aqueous dispersion, obtained by dispersing the solid preparation in water in a concentration of 1 W/V%, 7 or higher. The solid preparation of egualen sodium is packaged with its inside replaced with an inert gas.  <P>COPYRIGHT: (C)2010,JPO&INPIT
After signing the Institutional Review Board (IRB) approved Informed Consent Form (ICF), subjects will undergo a screening evaluation up to 28 days prior to dosing on Day 1 of Period 1. Subjects who satisfy the screening evaluation and who meet the inclusion and exclusion criteria will be enrolled in the study. Subjects will receive multiple doses of study drug according to their assigned sequence of treatment in Period 1. After completion of study procedures, a washout period will be completed prior to crossover to Period 2 to receive the second treatment in their sequence. Subjects will receive Regimens A (Esbriet® 801 mg three times daily with meals for 3 days) and B (EXCL-100, 1200 mg twice daily with meals) according to the randomization schedule. Pharmacokinetic (PK) blood samples will be taken on multiple days during the study periods.
Research participants will be instructed how to use a Concept 2 RowErg and will be provided instruction on basic rowing skills for beginners. Exercise training will gradually progress to 50 min of moderate-intensity exercise, on 3 days per week, for 12 weeks.
Antitussive compositions comprise glycyrrhetinic acid and/or a derivative thereof in admixture with one or more compounds selected from expectorants, known antitussives and antihistaminics.  The glycyrrhetinic acid derivatives may be a hemiester, salt of a hemiester, acyl derivative, xanthoglaboral or a derivative containing additional double bonds and/or keto groups as described in Specification 887,011.  Other specified components of the compositions are cocillana and ipecacuanha (expectorants), codeine, pholcodeine and dextromethorphan hydrobromide (antitussives), mepyramine maleate, diphenhydramine hydrochloride, antazoline sulphate and pheninolamine tartrate (antihistaminics) and Friar's balsam (a constituent of an inhalation composition).  The compositions may be in conventional pharmaceutical forms e.g. tablets, lozenges, syrups, suspensions, injections, suppositories, aerosols and inhalations. Specifications 843,132, 843,133 and 843,135 also are referred to.  Reference has been directed by the Comptroller to Specifications 843,133, 843,135, 843,136 and 870,651.
The study will include patients with PMR/GCA on ongoing prednisolone treatment in a low dose of \> 0 mg/day and ≤5mg/day. Eligible patients will undergo a Synacthen® test and 250 patients with a stimulated cortisol level \<420 nmol/l (biochemical adrenal insufficiency) will be randomised to either placebo or hydrocortisone supplemental doses during stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA and add supplemental hydrocortisone/placebo in situations of stress according to study protocol. In situations of severe stress (potential adrenal crisis) patients will receive open label hydrocortisone treatment according to routine clinical care. The duration of RESCUE is 6 months but stops earlier if the patient stops prednisolone treatment earlier. In case of a flare of PMR/GCA during the study where prednisolone is increased to \>5mg/day for e.g. 5 weeks the study is prolonged accordingly 5 weeks.

Seventy-five patients with stimulated cortisol ≥420 nmol/l (normal adrenal function) will be used as a reference group. The participants will undergo screening and baseline examinations, 3 month's reporting of HRQoL, and with patient consent follow-up through medical records on prednisolone treatment characteristics, and number of hospitalisations.
The invention is related to genetic engineering and can be used in biotechnology, medical science and agriculture to create gene therapy medicinal products. Gene therapy DNA vector based on gene therapy DNA vector VTvaflV carrying the target gene selected from a group of genes comprising BMP-2, BMP- 7, OPG, PDGFA, PDGFB to increase the expression level of this target gene In humans and animals is suggested. Wherein, gene therapy DNA vector VTvafl7-BMP-2, or VTvafl7-BMP-7, or VTvafl7-OPG, or VTvafl7-PDGFA, or VTvafl7-PDGFB has nucleotide sequence SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5, respectively. The gene therapy DNA vector does not contain nucleotide sequences of viral origin and there are no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals. A method of production of the specified vector, the method of use of the vector, Escherichia coli strain carrying the specified vector, as well as a method of production of the specified vector on an industrial scale are also suggested.
PURPOSE:To have a taste for capsule type favorite material or drug without troubling other persons, by volatilizing a favorite material or drug contained together with a thermogenic reactant in the same capsule with the exothermic heat in breaking the above-mentioned capsule. CONSTITUTION:A capsule type favorite material or drug obtained by placing a favorite material or drug 2, e.g. an aromatic material such as nicotinic acid, menthol or caffeine, which is a component contained in tobacco or stimulating material and a thermogenic reactant 3 selected from materials quickly generating heat in oxidation, e.g. Li or Mg, and materials generating heat in reduction, e.g. silver oxide, and a filler 4 in a capsule 1, e.g. gelatin, broken by external force, charging the resultant capsule type favorite material (9a) into a pipe, rotating the upper and lower parts (7a) and (7b) of the pipe in the opposite directions, breaking the capsule into parts (9b) with protrusions (7d) and (7e), bringing the thermogenic reactant 3 into contact with the outside to generate heat rapidly by reaction with oxygen, and volatilizing the favorite material or drug 2.
For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.